Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Nordson Corporation manufactures precision dispensing equipment and systems for adhesives, coatings, sealants, biomaterials, and other fluids across industrial, medical, and consumer end markets. The company operates through three segments: Industrial Precision Solutions (adhesive dispensing for packaging, nonwovens, product assembly), Medical & Fluid Solutions (single-use medical components, microfluidic systems), and Advanced Technology Solutions (semiconductor, electronics, and advanced manufacturing equipment). With 55% gross margins and global manufacturing footprint spanning Americas, Europe, and Asia, Nordson benefits from razor-razorblades economics through consumable sales and aftermarket service revenue.
Nordson generates revenue through capital equipment sales (60-65% of revenue) and high-margin recurring revenue from consumables, spare parts, and service contracts (35-40%). The business model features strong switching costs as dispensing systems are integrated into customer production lines with proprietary nozzles, pumps, and control software. Pricing power derives from application engineering expertise, process validation requirements (especially medical/pharma), and total cost of ownership advantages where precision dispensing reduces material waste by 10-30%. Operating leverage is moderate-to-high with 25.5% operating margins, as incremental revenue flows through at 40-50% contribution margins given fixed R&D and SG&A infrastructure. Aftermarket parts and service carry 60-70% gross margins versus 50-55% for equipment.
Industrial Precision Solutions order rates, particularly packaging equipment demand tied to consumer goods production and e-commerce fulfillment center buildouts
Medical segment growth driven by single-use bioprocessing adoption, continuous glucose monitor production, and diagnostic test manufacturing capacity expansions
Semiconductor capital equipment orders for Advanced Technology Solutions, correlated with wafer fab equipment spending cycles and advanced packaging investments
Aftermarket revenue growth and mix shift toward higher-margin consumables and service contracts, indicating installed base utilization rates
Acquisition integration and margin expansion from bolt-on deals in medical devices, microfluidics, and specialty coating technologies
Automation and robotics integration reducing need for manual dispensing systems in certain applications, though Nordson increasingly partners with automation providers to embed dispensing technology
Shift toward sustainable packaging and circular economy potentially disrupting adhesive-based packaging systems, requiring R&D investment in recyclable and bio-based material dispensing technologies
Medical device regulatory changes (FDA, EU MDR) increasing compliance costs and lengthening product development cycles, though also creating barriers to entry for smaller competitors
Fragmented competition from regional equipment manufacturers in Asia offering lower-cost dispensing systems with 20-30% price discounts, particularly threatening in price-sensitive packaging applications
Vertical integration by large customers (semiconductor fabs, medical device OEMs) developing in-house dispensing capabilities for proprietary processes, reducing addressable market
Technology disruption in semiconductor packaging (chiplet architectures, advanced heterogeneous integration) requiring significant R&D investment to maintain relevance in next-generation processes
Acquisition integration risk with $300-500M annual M&A spend requiring successful technology integration and customer retention, particularly in medical microfluidics where Nordson lacks legacy presence
Foreign exchange exposure with 60% revenue outside U.S. and manufacturing footprint creating natural hedges but still subject to 200-300 bps earnings volatility from currency swings
moderate - Industrial Precision Solutions (50% of revenue) exhibits cyclical exposure to consumer goods production, automotive assembly, and durable goods manufacturing tied to industrial production indices. Medical segment (30%) provides counter-cyclical stability through healthcare procedure volumes and biopharma R&D spending. Advanced Technology segment (20%) correlates with semiconductor capital equipment cycles, which can swing ±30% year-over-year. Overall revenue typically declines 5-15% in recessions but recovers faster than broad industrials due to productivity-enhancing value proposition and non-discretionary medical exposure.
Rising rates have modest negative impact through two channels: (1) customer capital equipment purchase decisions face higher hurdle rates, potentially delaying projects 3-6 months, particularly for smaller packaging converters and contract manufacturers; (2) valuation multiple compression as high-quality industrial compounder trading at 21.5x EV/EBITDA faces re-rating pressure when risk-free rates rise. Partially offset by 69% debt-to-equity ratio where refinancing risk is manageable and interest coverage exceeds 15x. Medical segment demand relatively rate-insensitive due to regulatory-driven equipment upgrades and procedure volume growth.
Low direct exposure as customer base spans investment-grade consumer goods companies (P&G, Unilever, Nestle), large medical device OEMs (Medtronic, Abbott), and semiconductor manufacturers (TSMC, Intel). However, tighter credit conditions can delay capital equipment orders from mid-market packaging converters and contract manufacturers that rely on equipment financing. Nordson's own balance sheet strength (1.64x current ratio, $700M operating cash flow) provides flexibility to offer customer financing programs during credit stress, supporting market share gains.
quality growth and dividend growth investors seeking industrial compounders with 40-year dividend increase streak, 55% gross margins, 25% operating margins, and 16% ROE. Attracts long-term holders valuing recurring revenue model (35-40% aftermarket), diversified end-market exposure, and consistent 5-8% organic revenue growth through cycles. Recent 35% one-year return reflects multiple expansion as market rewards quality industrials with medical and semiconductor exposure. Less attractive to deep value investors given 6.0x price-to-sales and 21.5x EV/EBITDA premium valuations.
moderate - Beta typically 1.0-1.2 with lower volatility than cyclical industrials due to medical segment stability and recurring aftermarket revenue. Stock experiences 15-25% drawdowns during industrial recessions but recovers within 12-18 months. Quarterly earnings volatility muted by geographic diversification and backlog visibility, though semiconductor segment can create ±5% earnings surprises tied to wafer fab equipment cycles.
